Bruker Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US1167941087
USD
48.38
1.09 (2.3%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Bruker Corp. stock-summary
stock-summary
Bruker Corp.
Pharmaceuticals & Biotechnology
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment. The Bruker BioSpin Group segment designs, manufactures and distributes enabling life science tools. The Bruker CALID segment designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as chemical, biological, radiological, nuclear and explosive detection products. The Bruker Nano segment designs, manufactures and distributes spectroscopy and microscopy instruments. The BEST segment develops and manufactures superconducting and non-superconducting materials and devices. It also focuses on nanomechanical testing instruments.
Company Coordinates stock-summary
Company Details
40 MANNING RD , BILLERICA MA : 01821
stock-summary
Tel: 1 978 66336601 978 6633660
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 100 Schemes (40.7%)

Foreign Institutions

Held by 204 Foreign Institutions (13.9%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Frank Laukien
Chairman of the Board, President, Chief Executive Officer
Dr. William Linton
Lead Independent Director
Ms. Bonnie Anderson
Independent Director
Ms. Cynthia Friend
Independent Director
Dr. Marc Kastner
Independent Director
Mr. John Ornell
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
797 Million
(Quarterly Results - Jun 2025)
Net Profit:
4 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5,386 Million (Small Cap)

stock-summary
P/E

49.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

27.41%

stock-summary
Debt Equity

1.30

stock-summary
Return on Equity

8.48%

stock-summary
Price to Book

2.99